文献速递头颈部肿瘤放疗姑息放疗与转移瘤放疗物理与技术

CT引导下放射性碘-125粒子植入作为两程及以上放疗后复发头颈癌挽救治疗的安全性与有效性

Safety and efficacy of CT-guided radioactive iodine-125 seed implantation as a salvage treatment for recurrent head and neck cancer after two or more courses of radiotherapy.
PubMed 文献 · Radiat Oncol · 2023-05-03

本研究收集33例接受两程及以上放疗后复发的头颈癌患者,行CT引导下放射性碘-125粒子植入挽救治疗。中位GTV为29.5 cc,术后中位D90为136.8 Gy;1年和2年局部控制率分别为47.8%和36.4%,1年和2年总生存率分别为41.3%和32.2%。作者结论认为该挽救治疗安全性和有效性可接受。

要点

  • 33例两程及以上放疗后复发头颈癌患者接受CT引导下放射性碘-125粒子植入,中位GTV为29.5 cc,术后中位D90为136.8 Gy。
  • 1年和2年局部控制率分别为47.8%和36.4%(中位局部控制时间10个月)。
  • 1年和2年总生存率分别为41.3%和32.2%(中位总生存时间8个月)。

核心结论

  • CT引导下放射性碘-125粒子植入作为挽救治疗,在两程及以上放疗后复发头颈癌中显示出可接受的安全性和有效性。

研究设计与样本

  • 收集33例接受两程及以上放疗后行CT引导下放射性碘-125粒子植入的复发头颈癌患者数据进行统计分析,既往放疗中位累积剂量为110 Gy。
  • 短期疗效采用实体瘤疗效评价标准(版本1.1)评估,不良事件采用常见不良事件术语标准(版本5.0)评估。
  • 本研究在中国临床试验注册中心数据库注册(注册号ChiCTR2200063261),注册日期为2022年9月2日。

主要发现

  • 中位大体肿瘤体积(GTV)为29.5 cc,术后90%靶区体积接受的中位剂量(D90)为136.8 Gy。
  • 不良反应包括疼痛加重3例(9.1%)、1至2级急性皮肤反应3例(9.1%)、2至3级晚期皮肤反应2例(6.1%)、1至2级早期黏膜反应4例(12.1%)、下颌骨坏死1例(3.0%)。
  • 1年和2年局部控制率分别为47.8%和36.4%(中位局部控制时间10个月)。
  • 1年和2年总生存率分别为41.3%和32.2%(中位总生存时间8个月)。
  • 无不良事件的发生与更好的局部控制相关。

关键数值与推荐

  • 短期疗效评估采用实体瘤疗效评价标准(版本1.1)。
  • 不良事件评估采用常见不良事件术语标准(版本5.0)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the past, patients with recurrent head and neck cancer (rHNC) who had previously received a high dose of radiation and were unable to undergo surgery were mainly treated with palliative chemotherapy due to the high incidence of side effects from re-irradiation. With the development of radiotherapy technology, re-irradiation of recurrent lesions by radioactive iodine-125 seed implantation (RISI) has been proposed as a feasible therapeutic approach. This study aimed to investigate the safety and efficacy of computed tomography (CT)-guided RISI in the treatment of rHNC after two or more courses of radiotherapy, and to analyze the prognostic factors. METHODS: Data of 33 patients with rHNC who received CT-guided RISI after two or more courses of radiotherapy were collected and statistically analyzed. The median cumulative dose of the previous radiotherapy was 110 Gy. Short-term efficacy was assessed by Response Evaluation Criteria in Solid Tumors (version 1.1) criteria, while adverse events were evaluated by Common Terminology Criteria for Adverse Events (version 5.0) criteria. RESULTS: The median gross tumor volume (GTV) was 29.5 cc, and the postoperative median dose to 90% of target volume (D90) was 136.8 Gy. For adverse reactions, enhanced pain was found in 3 (9.1%) patients, followed by grade 1 to 2 acute skin reactions in 3 (9.1%) patients, grade 2 to 3 late skin reactions in 2 (6.1%) patients, grade 1 to 2 early mucosal reactions in 4 (12.1%) patients, and mandibular osteonecrosis in 1 (3.0%) patient. Regarding the treatment efficacy, the 1- and 2-year local control (LC) rates were 47.8% and 36.4% (median LC time, 10 months), and the 1- and 2-year overall survival (OS) rates were 41.3% and 32.2% (median OS time, 8 months). The absence of adverse events was associated with better LC. CONCLUSIONS: CT-guided RISI, as a salvage therapy, demonstrated acceptable safety and efficacy in the treatment of rHNC after two or more courses of radiotherapy. TRIAL REGISTRATION: This study was registered at Chinese Clinical Trial Register database (Registration No. ChiCTR2200063261 ) in September 2, 2022.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Li Y, Jiang Y, Wang J, et al. Safety and efficacy of CT-guided radioactive iodine-125 seed implantation as a salvage treatment for recurrent head and neck cancer after two or more courses of radiotherapy. Radiat Oncol. 2023. PMID: 37138362. doi:10.1186/s13014-023-02254-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。